🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 19 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/07/2022 44,07 44,24 42,84 43,82 -0,14% 3,18% 553.400
14/07/2022 44,16 44,59 43,29 43,88 -1,17% 2,94% 420.600
13/07/2022 43,27 45,09 43,00 44,40 +1,60% 4,82% 620.500
12/07/2022 43,57 44,18 42,29 43,70 +0,62% 4,34% 483.900
11/07/2022 44,43 44,54 43,24 43,43 -2,91% 2,93% 605.700
08/07/2022 43,68 44,89 43,53 44,73 +1,52% 3,11% 388.800
07/07/2022 42,77 44,18 42,20 44,06 +2,68% 4,63% 615.600
06/07/2022 43,78 44,92 42,63 42,91 -1,99% 5,23% 948.200
05/07/2022 41,33 43,90 40,91 43,78 +4,61% 7,22% 1.117.900
01/07/2022 40,36 42,34 40,00 41,85 +4,47% 5,80% 512.500
30/06/2022 40,07 40,68 39,79 40,06 -0,84% 2,22% 627.000
29/06/2022 39,81 40,78 39,42 40,40 +1,15% 3,42% 704.600
28/06/2022 39,93 40,59 39,38 39,94 -0,27% 3,03% 957.100
27/06/2022 40,48 40,92 39,51 40,05 -0,42% 3,48% 748.800
24/06/2022 40,20 40,80 37,64 40,22 +0,27% 7,86% 1.594.500
23/06/2022 36,52 40,17 36,52 40,11 +11,35% 9,99% 1.380.600
22/06/2022 33,45 37,25 33,45 36,02 +5,72% 11,36% 2.133.300
21/06/2022 33,40 34,61 31,36 34,07 +19,92% 9,73% 5.019.800
17/06/2022 27,09 29,82 27,09 28,41 +8,19% 10,08% 1.628.200
16/06/2022 25,45 27,13 25,01 26,26 +0,27% 8,33% 583.200
15/06/2022 25,87 26,55 25,44 26,19 +2,07% 4,29% 719.500
14/06/2022 25,71 25,86 25,08 25,66 +0,23% 3,01% 795.100
13/06/2022 26,31 26,39 25,44 25,60 -4,48% 3,61% 857.400
10/06/2022 27,17 27,80 26,03 26,80 -3,77% 6,51% 728.400
09/06/2022 27,97 28,51 26,97 27,85 -1,03% 5,51% 500.900
08/06/2022 28,08 29,22 27,88 28,14 -0,81% 4,75% 627.400
07/06/2022 26,80 28,42 26,76 28,37 +5,31% 6,19% 705.900
06/06/2022 29,99 29,99 26,76 26,94 -6,03% 10,77% 666.300
03/06/2022 27,24 28,89 27,24 28,67 +5,52% 6,06% 808.300
02/06/2022 28,66 28,66 26,89 27,17 -6,57% 6,18% 1.195.200